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Previously unknown metabolites from the two macrolide immunosuppressants rapamycin
(sirolimus) and SDZ RAD [40-O-(2-hydroxyethyl)rapamycin] obtained after in vitro incubation
with human liver microsomes have been purified. Structure elucidation was performed by
nanoelectrospray ionization tandem mass spectrometry applying low energy collision acti-
vated dissociation. This ionization method is, as shown here, a powerful tool to determine
metabolic pathways by analysis of even low abundance products. Product ion spectra of the
isolated metabolites indicate a new kind of biotransformation reaction for rapamycin and SDZ
RAD. The proposed metabolic pathway starts with an ester hydrolysis which leads to a
ring-opened structure. A dehydration on C33–C34 and a supplementary hydrogenation at
C33–C34 result in a structure similar to the ring-opened isomer with an single bond at
C33–C34. (J Am Soc Mass Spectrom 2000, 11, 516–525) © 2000 American Society for Mass
Spectrometry
Rapamycin (sirolimus) [1] and SDZ RAD [40-O-(2-hydroxyethyl)rapamycin] are new immuno-suppresants which are structurally related with
the clinically used tacrolimus (FK 506). Both immuno-
suppressants are macrolide lactones with a 31-mem-
bered ring, SDZ RAD possessing an additional C2H4O
group at the C40 carbon atom. Because of this rather
slight difference in the structures of rapamycin and SDZ
RAD, similar biological activity, metabolism, and cor-
responding chemical and physical properties should be
expected. Schuurman et al. and Schuler et al. reported
that both substances showed the same activity in in vivo
experiments, whereas the in vitro activity of rapamycin,
compared with SDZ RAD, is two to three times higher
[2, 3].
Rapamycin is metabolized by enzymes of the P450
3A subfamily. The resulting transformation products
are mainly hydroxylated and/or demethylated [4–6].
Degradation products like the ester hydrolysis product
of rapamycin and the ring-opened rapamycin isomer
are described as well [5].
An approach for investigating unstable biomolecules
was found using soft electrospray ionization in mass
spectrometry (ESI-MS) [8–11]. Streit et al. described the
detection of rapamycin metabolites without fragmenta-
tion using high performance liquid chromatography
(HPLC)-ESI-MS [6]. They were thus able to identify the
kind of biotransformations leading from rapamycin to
its metabolites. Information concerning the structure of
these metabolites, hence elucidation of the transforma-
tion position, was obtained using tandem ESI-MS [6].
Four rapamycin metabolites were previously deter-
mined according to the methods of Iwasaki et al. [7],
who analyzed metabolites of tacrolimus using fast-atom
bombardment (FAB)-MS and NMR. Concerning these
investigations, the structures of the following metabo-
lites or degradation products were identified: 39-O-
demethyl-, 16-O-demethyl-, 12-hydroxy-, 34-hydroxy
rapamycin (ester hydrolysis product of rapamycin), and
the dehydrate of 34-hydroxy rapamycin [5, 6]. The last
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mentioned metabolite corresponds to a ring-opened
isomer of the mother substance. Furthermore, multiple
hydroxylated and demethyl-hydroxylated metabolites
were described whose presence was indicated by the
detected molecular mass [6].
The structures of three SDZ RAD metabolites have
been determined by means of ESI-MS, too: 16-O-de-
methyl-, 34-hydroxy-SDZ RAD, and the SDZ RAD
isomer [12]. Their structures match those of the corre-
sponding rapamycin metabolites. This could be ex-
pected regarding the similar structures of rapamycin
and SDZ RAD at the relevant molecule regions. We
developed an HPLC method for isolating rapamycin
metabolites after in vitro incubation of rapamycin with
human liver microsomes, which is also suitable for
separating SDZ RAD metabolites. We determined [M 1
Na 1 2O]1 dihydroxylated, [M 1 Na 1 O]1 monohy-
droxylated, [M 1 Na 2 CH2]
1 demethylated metabo-
lites and [M 1 Na]1, an isomer of rapamycin and SDZ
RAD using HPLC coupled with an electrospray mass
spectrometry (LC-ESI-MS). Demethyl-monohydroxy-
lated metabolites as proposed for rapamycin by Streit et
al. [6] could not be detected in the expected polar region
of the LC-MS chromatogram. Instead we found a me-
tabolite giving an ion [M 1 Na 1 2]1 with a retention
time in the LC-MS chromatogram between the rapamy-
cin isomer and rapamycin. From the much lower polar-
ity of the determined compound we assume that the
rapamycin metabolite with a molecular weight m/z 938
is not the sodium adduct of a demethyl-hydroxylated
metabolite [M 1 Na 2 CH2 1 O]
1.
SDZ RAD shows the same effect as well, because we
found a metabolite giving an ion [M 1 Na 1 2H]1 m/z
982. We supposed that this metabolite is to have a
completely new structure, not yet described for macro-
lide immunosuppressiva like FK 506, SDZ RAD, or
rapamycin.
The aim of this study was to isolate and identify a
new rapamycin and SDZ RAD metabolite generated by
human liver microsomes. We separated these metabo-
lites by means of HPLC with UV detection and charac-
terized them using HPLC-ESI-MS. After having isolated
the metabolites we identified their structures using
nano-electrospray ionization tandem mass spectro-
metry (nano-ESI-MS/MS). Tandem mass spectrometry
with a nano-electrospray interface is a powerful analyt-
ical technique for low abundance biomolecules. It de-
lineates connectivity relationships between precursor
and product ions and is well suited for structure
elucidation of organic molecules.
Experimental
Materials
Bicinchonich acid and bovine serum albumin for pro-
tein determination were purchased from Sigma (Deis-
enhofen, Germany). Chemicals for the NADPH regen-
erating system were obtained from Boehringer
Mannheim (Germany). All organic solvents and water
used for preparation of buffers were of HPLC grade and
purchased from Merck (Darmstadt, Germany).
Rapamycin was a kind gift from Wyeth-Ayerst Re-
search, Princeton, NJ. SDZ RAD was provided from
Novartis Pharma, Basel, Switzerland. Peak identifica-
tion and purity checking of all samples were done with
a variable UV monitor Merck/Hitachi.
Figure 1. Structure of rapamycin, SDZ RAD, and tacrolimus.
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Isolation of Human Liver Microsomes
Human liver samples were obtained from the Klinik fu¨r
Abdominal und Transplantations-chirurgie of the
Medizinische Hochschule Hannover. The collection of
human liver samples for research was approved by the
Ethical Committee of the Medizinische Hochschule
Hannover. Isolation of human liver microsomes was
performed by standard centrifugation techniques [13]
with the modification that phosphate buffer (pH 7.4)
was used instead of tris buffer.
The microsomes were pooled, and the protein con-
centration determined according to Smith et al. [14] was
38 mg/mL.
Metabolism of Rapamycin by Human Liver
Microsomes
500 mL of NADPH regenerating system were dissolved
in 1.0 mL sodium phosphate buffer (0.1 mol/L, pH 7.4).
NADPH regenerating system consisted of 2 mmol/L
EDTA, 10 mmol/L MgCl2, 0.84 mmol/L NADP, 18
mmol/L isocitric acid, and 667 U/L isocitrate dehydro-
genase dissolved in 0.1 mmol/L phosphate buffer (pH
7.4). 50 mL microsome concentrate were added to this
solution and the reaction was started with 20 mL of
immunosuppressant (rapamycin and SDZ RAD), dis-
solved in acetonitrile at a concentration of 2.0 mg/mL.
The reaction mixture was incubated for 90 min at 37 °C.
The reaction was terminated by protein precipitation
with 500 mL acetonitrile.
HPLC Separation with UV Detection
After protein precipitation the mixtures of the metabo-
lites were extracted using a column-switching proce-
dure. For automatic extraction of the samples, the
HPLC system consisting of a Merck Autosampler
L-7200 (Merck/Hitachi, Darmstadt, Germany), a col-
umn oven, a Merck pump system L-6200/L-6000, and
the Merck 655A Variable Wavelength UV-Detector, was
supplemented with an external six port Rheodyne
valve, a Knauer micropump (WellChrom Micro-Star
K-100, Knauer GmbH, Berlin, Germany), and a pre-
column cartridge (Schambeck GmbH, Bad Honnef, Ger-
many). Data acquisition, integration, processing of the
chromatograms, and switching between the two posi-
tions of the external Rheodyne valve were performed
and controlled by software of the SRI PeakSimple
Figure 2. Flow diagram of the HPLC instruments using column-switching technique for extraction
of the immunosuppressiva and metabolites. At the beginning of a run the valve is in position I, this
means the injected sample is flushed with the external pump from the slope to the pre-column (10 3
4 mm i.d., 10 mm, Hypersil ODS). The water soluble components pass through the pre-column and
flush with the water in waste, while rapamycin and its metabolites are adsorbed on the pre-column
material. After 3 min of flushing water through the pre-column the valve is switched to position II.
The solvent mixture from the gradient pump system flows in the backflush mode through the
pre-column to the analytical column where the separation begins.
518 HALLENSLEBEN ET AL. J Am Soc Mass Spectrom 2000, 11, 516–525
Chromatography Data System (Schambeck GmbH, Bad
Honnef, Germany).
Flow rates of both pumps were set to 0.7 mL/min.
The whole procedure of concentrating purification on
one hand and elution on the other hand were deter-
mined by the position of the external valve. The exter-
nal pump uses water for transporting samples on the
pre-column (10 3 4 mm i.d., 10 mm Hypersil) and
washing the samples. The column switching procedure
is presented in Figure 2. For elution and separation of
the components, we used a gradient with acetonitrile
and water with 0.01% formic acid (adjusted to pH 3).
An analytical column (250 3 4 mm i.d.) filled with
RP-C18 Nucleosil 100 Å, particle size 3 mm (Schambeck
GmbH, Bad Honnef, Germany), was used. The samples
were separated at a flow rate of 0.7 mL/min and the
gradient was: 0–3 min 58% acetonitrile, 30 min 65%
acetonitrile, 35 min 80% acetonitrile, and 5 min in up to
90% acetonitrile. After 40 min the valve switched back
to the starting position and the analytical and pre-
column were reconditioned at initial conditions within
5 min. The detector was set at 276 nm and the temper-
ature of the column oven was 40 °C. The injection
volume was 200 mL of the sample each time.
After UV detection the metabolites were manual
collected for off-line investigation using ESI-MS/MS.
HPLC-ESI-MS Assay
The analyses were performed on an HP 1090 A liquid
chromatograph (Hewlett-Packard, Waldbronn, Ger-
many) equipped with the same column-switching tech-
nique described for HPLC separation. The analytical
column was a 250 3 1 mm RP-C18 column filled with
Nucleosil 100 Å, particle size 3 mm (Fa. Dr. A. Maisch,
Ammerbuch, Germany). The oven temperature was
40 °C and the flow rate was 40 mL/min. Solvents and
the elution gradient were the same as described above.
After separation the samples were directly flushed into
the API electrospray interface from the HP mass spec-
trometer (HP 5989 B MS-Engine connected with a HP
59987 A API-Electrospray LC-MS Interface, Waldbronn,
Germany). The temperature of the nitrogen drying gas
Figure 3. HPLC chromatograms of incubation of SDZ RAD A
and rapamycin B with human liver microsomes at 37 °C for 90 min.
Figure 4. UV spectrum of rapamycin (top) and the rapamycin
metabolite RM (bottom).
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was 350 °C and the flow was 10 L/min. The voltage of
the capillary was set to 24000 V, the end plate was set
to 23500 V, the cylinder electrode was set to 6000 V,
and the capillary exit voltage was 300 V. For peak
identification full-scan mass spectra were acquired in
positive ion mode. To increase the sensitivity, selected-
ion monitoring (SIM) for determination of the [M 1
Na]1 was used: rapamycin and its isomer (m/z 937),
demethyl-rapamycin (m/z 923), hydroxy-rapamycin
(953), dihydroxy-rapamycin (m/z 969), and RM (m/z
939); SDZ and its isomer (m/z 981), demethyl SDZ RAD
(m/z 967), hydroxy SDZ RAD (m/z 997), dihydroxy SDZ
RAD (m/z 1013), and SM (m/z 983).
ESI-Tandem MS Assay
Mass spectrometric determinations and tandem quad-
rupole experiments (CAD experiments, collisionally
activated dissociation) were carried out on an API III1
triple quadrupole mass spectrometer (PE-SCIEX, To-
ronto, Canada) equipped with either the standard elec-
trospray ionization source or with an in-house build
nanospray ionization source. Instrument parameters
were determined daily by calibration with the polypro-
pyleneglycol standard as recommended by the manu-
facturer. Standard electrospray ionization was per-
formed at flow rates of 5 mL/min using a syringe pump
(Harvard Apparatuses, Saint-Laurent, Quebec, Canada)
and a 192 mm o.d., 50 mm i.d. fused silica capillary
(Polymicro Technologies, Phoenix, AZ) from the sy-
ringe (Hamilton, Bonaduz, Switzerland) to the electro-
spray source. Nanospray was carried out using com-
mercially available nanotips (Protana, Odense,
Denmark), filled with 5–10 mL of the metabolite solu-
tion in 50% acetonitrile, 0.5% formic acid in water
(v:v:v). The adjustment of the needles was confirmed by
observing a maximum of signal for the metabolite. The
nanospray ionization was carried out at 600–800 V
ionization voltage and 100 V interface plate voltage.
The orifice voltage was adjusted to obtain maximum
signal intensity. CAD experiments were carried out
after obtaining maximum signal intensity using the
Figure 5. Proposal metabolic pathway for the formation of the rapamycin metabolite RM. The same
pathway is supposed for the SDZ RAD metabolite SM.
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orifice voltage as determined before. Argon was used as
collision gas with a collision gas thickness of 300–400 as
read from the instrument. Collision energy was tuned
manually from 20 to 80 eV during the MS/MS experi-
ments to obtain the full range of fragments. The Q1 was
set to the determined mass of the single charged ion of
the metabolite and Q3 was scanned from 100 to 1000 u,
at 0.5 u step. Up to 200 individual spectra were collected
for an optimal signal to noise ratio. Data were collected
and analyzed using the software supplied with the
instrument.
NMR experiments
NMR experiments were carried out with rapamycin, the
ring-opened isomer, and the rapamycin metabolite RM.
All 2D NMR spectra were measured with a Bruker
AM-600 spectrometer (600 MHz). COSY, TOCSY,
HMQC, and HSQC were measured in DMSO (d6).
Temperature in all experiments was 20 °C. TOCSY
spectra were recorded by a data matrix 1K 3 256
points, mixing time 50 ms. HMQC spectra were re-
corded with a relaxation delay 1.000–1.711 s, sine bell
117–131 ms, and HSQC spectra with a relaxation delay
1.000 s, 13C garp1 decoupling, sine bell 8 ms, shifted by
28 ms.
Results and Discussion
After incubating the immunosuppresants rapamycin
and SDZ RAD with human liver microsomes, the
metabolites were analyzed using LC-ESI-MS and
mainly characterized from to their molecular masses.
Referring to the mother substance as well as the metab-
olites, we did not detect protonated molecules [M 1
H]1, but mainly the stable sodium adducts [M 1 Na]1,
and sometimes potassium adducts [M 1 K]1 [15].
The HPLC chromatogram of both immunosuppres-
sants clearly indicates a division of the areas of the
dihydroxylated, the monohydroxylated, and the de-
methylated metabolites, as well as of the ring-opened
isomers and the unmodified mother substances. This
proves that, in spite of the molecular size of rapamycin
and SDZ RAD, modification such as hydroxylation in
one position leads to a remarkable change of the polar-
ity of the whole molecule. As hydroxylation and de-
methylation yield more polar substances, these elute at
shorter retention times in HPLC. These metabolites
possess an intact macrolide ring; therefore there is no
free carboxyl group which would influence the polarity
[6]. On the other hand, the isomers of both immuno-
suppressants occur in a ring-opened structure with a
free carboxyl group and a double bond between C33–
C34 [4, 5, 12]. This affects retention time, as shown in
Figure 6. CAD spectrum of rapamycin and the rapamycin me-
tabolite RM after HPLC separation.
Figure 7. CAD spectrum of SDZ RAD and the SDZ RAD
metabolite SM after HPLC separation.
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Figure 3. Interesting are the metabolites RM and SM
which may be found in the HPLC chromatogram (and
therefore also in relation to their polarity) between the
isomers and the mother substances. Their metabolites
possess a UV spectrum similar to those of rapamycin
and SDZ RAD. This UV absorbance is caused by a p
system which on conjugation shows a characteristic
splitting of the bands. This splitting can be observed in
Figure 8. Structures of proposal fragments for the rapamycin as well as the SDZ RAD metabolite,
RM and SM.
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rapamycin and SDZ RAD as well as in RM and SM,
proving an intact triene system in RM and SM. Figure 4
presents the UV spectrum of RM in comparison to that
of rapamycin. Differences may be seen in the absorption
only, as RM occurs in significantly lower concentration
after incubation in relation to rapamycin.
By means of HPLC-ESI-MS the molecular masses of
the metabolites RM (m/z 939) and SM (m/z 983) were
determined. Both metabolites prove to have a mass
difference of 2 Da in relation to their mother substances
rapamycin (m/z 937) and SDZ RAD (m/z 981). With
regard to this fact one may conclude that RM and SM
are either demethylated-hydroxylated metabolites
[M 1 OH 2 CH2 1 Na]
1 or reduction products [M 1
2H 1 Na]1. In the literature metabolites which, how-
ever, could not be separated by chromatography were
described as demethylated hydroxylated [6, 16, 17]. As
already mentioned above, this possibility is rather un-
likely, as in such case the metabolites should show
retention times between the di- and mono-hydroxy-
metabolites.
If one accepts a reduction, there are numerous pos-
sibilities due to the size of these molecules. Thus,
reduction of a functional group as well as of a double
bond must be taken into account. Hydrogenation of
double bonds have been described in the biotransfor-
mation of terpenoids as well as in the metabolism of
steroids [18]. In macrolide immunosuppressants like
tacrolimus (FK506), rapamycin, and SDZ RAD such a
reaction is not known so far. As the UV spectra of the
metabolites RM and SM still indicate the characteristics
for the triene system, a reduction at this site can be
excluded. Accepting that the metabolites RM and SM
are formed directly from the ring-opened isomer of
their mother substances, the C29–C30 double bond can
be reduced.
On incubation of rapamycin and SDZ RAD with
human liver microsomes it could be demonstrated that
the metabolites RM and SM are formed in trace
amounts only, if the incubation time is less than 30 min.
The corresponding ring-opened isomers, however, are
formed in considerable amounts. If one incubates more
than 1 h, the formation of RM and SM is increased. At
the same time the formation of the corresponding
isomers decreases. Therefore, it may be assumed that
the metabolites RM and SM are formed from the
corresponding ring-opened isomers. To assess this, we
have isolated the isomer of rapamycin after HPLC,
which then was incubated with human liver micro-
somes according to the method described. After analy-
sis of the incubation solution the rapamycin metabolite
could be identified unambiguously, proving that RM is
a metabolite of the second generation. Control experi-
ments without NADPH or with denatured microsomes
were performed. These incubations result in the un-
modified ring-opened isomer; no degradation products
were observed. A proposal for the metabolic pathway
of the formation of RM is given in Figure 5.
Because of the analogy of rapamycin and SDZ RAD
one can accept that the conclusion mentioned above is
valid also for the metabolite SM.
To verify this hypothesis, the relevant rapamycin
and SDZ RAD metabolites were isolated by means of
the developed HPLC method. Afterwards, the metabo-
lites were off-line investigated by using ES-MS.
Because of the small amounts of material, analysis of
these metabolites was impossible by standard electro-
spray ionization using 5 mL/min flow rates. Because of
its higher sensitivity, little sample consumption and
reduced influence of salts and other substances on the
ionization, a modified ESI method, nanospray ioniza-
tion was used [19]. Even for low abundance metabolites
like the isolated rapamycin and SDZ RAD metabolites,
this off-line technique allowed the determination of
their structure by tandem quadrupole mass spectrometry.
For the examination of structurally significant frag-
mentation reactions only the sodium adducts of the
molecular ions were used.
Fragmentation of the Metabolites
Figure 6 demonstrates the collisionally activated disso-
ciation (CAD) spectra of rapamycin and the new corre-
sponding metabolites RM as well as the spectra of SDZ
RAD and the new corresponding metabolites SM (Fig-
ure 7). Compared to SDZ RAD the spectra of rapamycin
show, as expected, the same fragmentation patterns and
similar intensity relations of the fragments. The charac-
teristic fragments are marked. Compared with the
mother substance, they all show a mass difference of 2 Da.
The major fragmentation reactions can be attributed
to a-cleavage in the neighbourhood of a hetero-atom as
well as the loss of small, neutral molecules. Thus the
methoxy group at C16 is split off very easily forming a
more stable tetraene system. This results in the forma-
tion of the fragment ion [M 1 Na 2 CH3OH]
1 m/z 907
Figure 9. Structure of the new metabolite of rapamycin (RM)
and SDZ RAD (SM).
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(RM) and m/z 951 (SM) (Figures 6 and 7). Like the
additionally dehydrated fragment B, this fragment A
contains the examined molecular region between C33
and C34. The suggested structures for the fragments A
and B are shown in Figure 8.
The cleavage of the bond between C8 and C9 leads to
the formation of fragment C {[Mf 1 Na]
1 where Mf 5
mass of fragment; m/z 766 (RM) and m/z 810 (SM)} and
D, with the methoxy group and, furthermore, water
being split off as neutrals {[Mf 1 Na]
1 m/z 734 (RM)
and m/z 778 (SM)}. Fragment D undergoes a loss of CO
to yield the fragment E {[Mf 1 Na]
1 m/z 705 (RM) and
m/z 749 (SM)}. Another fragment containing the molec-
ular region between C33 and C34 is fragment F (Figure
8), where the bond between C14 and C15 was cleaved
and the methoxy group at C16 was split off as an
alcohol. This resulted in a tetraene system also con-
tained in fragments A and B. A very characteristic
fragment is the stable fragment G {[Mf 1 Na]
1 m/z 347
(RM) and m/z 392 (SM)}, which describes a possible
reduction position at C33–C34.
The fragment ions [Mf 1 Na]
1 m/z 614, 582, 441, 409,
and 365 in the CAD spectrum of the rapamycin metab-
olite RM correspond to the fragments of the unmodified
mother substance. Referring to the rapamycin spec-
trum, a fragmentation pattern with a shift of 44 Da was
found for RAD SDZ metabolites (Figure 7).
Thus the isolated metabolites of rapamycin and SDZ
RAD could be verified as reduction products of the
isomers (Figure 9). Confirmation of the suggested struc-
tures of RM were carried out using two-dimensional
NMR experiments (COSY, TOCSY, HSQC, HMQC).
Rapamycin and the ring-opened isomer were used as
reference substances. All chemical shifts could be deter-
mined. Signals of the C33–C34 region in all three
substances demonstrate typical shifts of an ester group
(rapamycin), an alpha–beta unsaturated, and a satu-
rated ketone (ring-opened isomer and RM). These
chemical shifts are shown in Table 1. The reduction of
the double bond between C33 and C34 has not been
described so far for any of the metabolites of immuno-
suppressant macrolides. Therefore an additional reac-
tion in the metabolic pathway of rapamycin and SDZ
RAD has been described.
Conclusion
Nanospray 1 tandem-mass spectrometry proves to be
the method of choice for investigation of sensitive and
low abundance metabolites. Compared to the mother
substances the new metabolites RM and SM present a
molecule mass with a differences of 2 Da. The CAD
spectra of the mother substances, rapamycin and SDZ
RAD, serve as a template for the investigation of a
possible fragmentation pathway of the new metabolite
of rapamycin (RM) as well as those of SDZ RAD (SM).
Comparison of the CAD spectra of the metabolites and
the mother substances indicated characteristic frag-
ments with a mass difference of 2 Da, too. These mass
differences in the CAD spectra point to the reduction of
a double bond. The possibility of a reduction of the
ring-opened isomer at C33–C34 was confirmed by two-
dimensional NMR spectra. The presented metabolic
reaction has not been reported so far for macrolide
immunosuppressants like rapamycin, SDZ RAD, and
tacrolimus. Further investigations should examine the
biological activity of the isolated and identified metab-
olites RM as well as SM.
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